Document is current
Any future updates will be listed below
-
Authors
Raymond, Joel S
Rehn, Simone
James, Morgan H
Everett, Nicholas A
Bowen, Michael T https://orcid.org/0000-0002-8965-4136
-
Funding
Funding for this research was provided by:
Australian National Health and Medical Research Council (1092046, 1166044)
National Institute on Drug Abuse (R00 045765)
- License Information
-
More Information
Article History
Received: 22 February 2024
Accepted: 9 April 2024
First Online: 19 July 2024
Declarations
:
: Experiments reported in this study adhered to guidelines set out in the <i>Australian code for care and use of animals for scientific purposes (8th edition, 2013)</i> and experimental procedures were approved by The University of Sydney Animal Ethics Committee (AEC protocol number: 2021/1891).
: Not applicable.
: In addition to his academic role, MTB is co-founder and Chief Scientific Officer of Kinoxis Therapeutics Pty Ltd, an Australian-based company developing novel small molecule treatments for brain disorders, including the treatment of substance use disorders and social impairments in psychiatric conditions. NAE is Head of Behavioural Neuroscience at Kinoxis Therapeutics. MTB and NAE receive research funding from Kinoxis Therapeutics. The work presented in this manuscript is unrelated to MTB’s and NAE’s role with Kinoxis Therapeutics. The remaining authors (JSR, SR, and MHJ) declare that they have no competing interests.
